Navigation Links
Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
Date:6/16/2009

Company Enrolls First Patient into SPIRIT PRIME Trial in the United States

ABBOTT PARK, Ill., June 16 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced the initiation of SPIRIT PRIME, a clinical trial to study the performance of the company's next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System, currently an investigational device, for the treatment of coronary artery disease. Results from SPIRIT PRIME will be used to support the regulatory filing for XIENCE PRIME in the United States. The first patient was enrolled into the SPIRIT PRIME clinical trial at Hillcrest Medical Center in Tulsa, Okla., by Rajesh Chandwaney, M.D.

XIENCE PRIME utilizes the same well-studied drug and proven biocompatible polymer as Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System. In addition, it offers a novel stent design and a modified delivery system designed for greater flexibility and improved deliverability. XIENCE PRIME uses cobalt chromium technology, which allows for very thin struts while maintaining strength to support the vessel as well as excellent visibility under X-ray during the stent implantation procedure. XIENCE PRIME is based upon the proven design of the MULTI-LINK(R) family of stents, which is the most widely used stent platform in the world - with more than 2 million implants worldwide. The company expects to launch XIENCE PRIME in a broad size matrix with sizes up to 38 mm in Europe later this year.

"XIENCE PRIME carries the same successful drug and polymer as the XIENCE V stent. Its stent platform and delivery balloon are designed to be highly deliverable, and as such, XIENCE PRIME has the potential to simplify procedures in challenging cases," said Marco A. Costa, M.D., Ph.D., FACC, FSCAI, professor of medicine, director of the Interventional Cardiol
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Abbott Declares 342nd Consecutive Quarterly Dividend
2. Abbott Announces Launch of Next-Generation Embolic Protection System
3. Abbott Announces New EAS(R) Myoplex(R) Strength Formula Nutrition Shake and Debuts Bottle Packaging
4. Abbotts TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets
5. Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
6. Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia
7. Abbott to Present at Goldman Sachs Global Healthcare Conference
8. Feeding America and Abbott Partner For Hurricane Relief
9. Abbotts XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, Real World Patients in SPIRIT V Study
10. Abbott Announces EuroPCR 2009 Activities
11. Victory! Colombian Government Cuts Price of Abbotts Lifesaving AIDS Drug Kaletra 55%, Says AHF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... When it comes to excess pounds and blood pressure, all ... The research found that belly fat -- the proverbial ... pressure more than overall body fat. It,s well known ... it wasn,t clear how the location of fat in the ... Texas Southwestern Medical Center in Dallas. Reporting Sept. 1 ...
(Date:9/2/2014)... Moroccan Eco-Biologics’ new one-of-a-kind Vitality Hair Recovery ... the foundation of all natural Moroccan plant extracts to ... There is nothing similar to Vitality Hair Recovery cream ... is a commonly encountered problem for men and women ... been limited to existing medications offering mediocre results, considerable ...
(Date:9/2/2014)... 2014 National law firm, ... has filed an application for attorneys’ fees and ... action litigation brought over Flushmate flushing mechanisms. In ... Counsel in this litigation includes Birka-White Law Offices; ... Partners, LLP; Levin Fishbein, Sedran & Berman, LLP; ...
(Date:9/2/2014)... Lauderdale, Florida (PRWEB) September 02, 2014 ... Commission Accredited teleradiology and telemedicine solutions provider, including ... with its innovative and technologically advanced services. The ... Al Shifa Hospital in Kuwait. , Founded and ... in Kuwait, Dar Al Shifa began as a ...
(Date:9/2/2014)... pleased to announce that the following papers will ... ESC Congress 2014, taking place in Barcelona, Spain, ... Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable ... a randomised, single-blind, non-inferiority trial, Windecker et al ... thickness, surface polymer, and drug release have improved ...
Breaking Medicine News(10 mins):Health News:'Spare Tire' May Be Especially Bad for Your Blood Pressure 2Health News:New All Natural, Organic Hair Recovery Products by Moroccan Eco-Biologics, Restore Lost Hair with No Side Effects 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 3Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 2Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 3Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 4Health News:The Lancet: European Society of Cardiology Congress 2014 media alert 2
... finds chlorthalidone most likely to prevent heart failure, ... Tried-and-true diuretics maintain their status as the best ... high blood pressure, new research concludes. , The ... a calcium channel blocker, an ACE inhibitor and ...
... Nov. 18 The U.S. Agency for International Development (USAID) ... up with Chicago Cubs Charities Nov. 17 to donate $100,000 ... Basic School and Education Center for Integrated Health (CESI). , ... and...Loyola and Creighton (universities) to help children and their families ...
... Release Statewide Data , HARRISBURG, Pa., Nov. 18 Pennsylvania is ... and adults living with autism, according to the Pennsylvania Autism Census ... , "With the release of this report, Pennsylvania becomes the first ... to meet the needs of the rapidly growing population of children ...
... The National Patient Safety Foundation (NPSF) today issued the following position ... The National Patient Safety Foundation recognizes vaccine-preventable, ... and supports mandatory, influenza vaccination of ... patients, health care workers, and the community. NPSF appreciates, ...
... Nov. 18 Hospice workers have seen patients hang onto ... from the Frances Payne Bolton School of Nursing and the ... will study what drives the dying to resolve unfinished business. ... Prince-Paul from nursing and Julie Exline from arts and sciences ...
... at Mount Sinai School of Medicine set out to ... years: How do dietary restrictionand the reverse, overconsumptionproduce protective ... in a two-part study led by Charles Mobbs, PhD, ... at Mount Sinai School of Medicine, published in the ...
Cached Medicine News:Health News:Diuretics Still Best Treatment for High Blood Pressure 2Health News:USAID, Cubs Charities Make a Grand Slam for Health and Basic Education 2Health News:PA Governor Rendell: New Report Shows Demand for Autism Services will Continue to Rise 2Health News:National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 2Health News:National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 3Health News:Research Collaboration Focuses on Unfinished Business at the End of Life 2Health News:Scientists find molecular trigger that helps prevent aging and disease 2Health News:Scientists find molecular trigger that helps prevent aging and disease 3
(Date:9/2/2014)... -- Actavis plc (NYSE: ACT ) today ... has accepted for filing Actavis, New Drug Application (NDA) ... diarrhea and abdominal pain in men and women with ... eluxadoline has been granted priority review status by the ... "The NDA filing of eluxadoline marks an important ...
(Date:9/2/2014)... CITY, Calif. , Sept. 2, 2014  Abaxis, ... company manufacturing point-of-care blood instrumentation and consumables to the ... Clint Severson , Chairman and Chief Executive Officer, will ... Wednesday, September 10, 2014 at 10:20 a.m. ET. The ... York in New York City . ...
(Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014   Mast Therapeutics, ... Executive Officer, Brian M. Culley , will present at the ... Tuesday, September 9, 2014 at 2:55 p.m. Eastern time in the ... New York . Interested parties can ... Therapeutics web site at www.masttherapeutics.com . An archived presentation will ...
Breaking Medicine Technology:Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 2Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 3Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 4Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference 2Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th 2Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th 3
... , WASHINGTON, Dec. 14 ... counsel on global and domestic communications and issues management, ... PositiveID Corporation (Nasdaq: PSID ) to serve as ... will conduct media relations for PositiveID,s corporate communications and ...
... , NEW HAVEN, Conn., ,Dec. 14 /PRNewswire-FirstCall/ ... today announced that it had received a complete response ... related to its New Drug Application ("NDA") for Onrigin(TM) ... indicates that the FDA cannot approve the Company,s NDA ...
Cached Medicine Technology:Gibraltar Associates Named Agency of Record for Health Information and Diagnostic Provider PositiveID Corporation 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: